Jazz Pharmaceuticals plc (JAZZ) Stock Forecast
JAZZ analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 22 analysts
- Price target
- $294.64 average of analyst targets
- Upside to target
- +40.1% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $5.66
- 52-week range
- $131.16 – $261.62
JAZZ analyst ratings
22 analystsNumber of analysts at each rating.
JAZZ price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
JAZZ earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.56 | −$4.71 | $6.95 | $8.13 | −68.5% | 19 |
| Current fiscal year (2026) | $21.12 | $13.35 | $26.15 | $8.38 | +152.0% | 19 |
| Next fiscal year (2027) | $26.05 | $21.82 | $31.39 | $21.12 | +23.4% | 19 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
JAZZ revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.21B | $1.17B | $1.24B | +7.1% | 18 |
| Current fiscal year (2026) | $4.72B | $4.62B | $4.81B | +10.7% | 21 |
| Next fiscal year (2027) | $4.99B | $4.69B | $5.27B | +5.7% | 21 |
JAZZ EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
JAZZ revenue: reported and forecast
JAZZ EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $6.39 | $6.49 | $6.47 | $3.10 | $2.56 | −59.9% | 1 up · 5 down |
| Current fiscal year (2026) | $25.39 | $25.05 | $25.03 | $21.65 | $21.12 | −16.8% | 1 up · 4 down |
| Next fiscal year (2027) | $25.78 | $25.77 | $25.77 | $25.82 | $26.05 | +1.1% | 3 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
JAZZ earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; JAZZ beat in 6 of 12.
What analysts expect from JAZZ
22 analysts cover Jazz Pharmaceuticals; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $294.64, 40.1% above the latest close of $210.23. Analysts expect earnings of $21.12 per share for 2026, +152.0% from a year earlier. For 2027 the average estimate is $26.05 per share on revenue of $5.0 billion. Jazz Pharmaceuticals beat the EPS estimate in 6 of the last 12 quarters.
Related: JAZZ income statement, JAZZ key metrics, JAZZ chart. See the JAZZ stock overview for the latest quote and news.
JAZZ forecast FAQ
What is Jazz Pharmaceuticals's price target?
The average analyst price target for Jazz Pharmaceuticals is $294.64, 40.1% above the latest close of $210.23.
Is Jazz Pharmaceuticals a buy, hold or sell?
Of 22 analysts covering Jazz Pharmaceuticals, 13 rate it a strong buy, 7 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Jazz Pharmaceuticals's EPS forecast?
Analysts forecast $21.12 per share for 2026 (range $13.35 to $26.15); for 2027 the estimate is $26.05.
What is Jazz Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $4.7 billion, growth of 10.7%; for 2027 it is $5.0 billion.
When does Jazz Pharmaceuticals report earnings?
Jazz Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes; the EPS estimate is $5.66.
Does Jazz Pharmaceuticals usually beat earnings estimates?
Jazz Pharmaceuticals reported EPS at or above the analyst estimate in 6 of the last 12 quarters.